PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33317473-3 2020 Lusutrombopag, a thrombopoietin receptor agonist, can increase the platelet count in such patients when invasive procedures are scheduled. lusutrombopag 0-13 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 17-40 33797208-4 2021 The model was applied to thrombopoiesis of a thrombopoietin receptor agonist, lusutrombopag. lusutrombopag 78-91 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 45-68 34386595-3 2021 Lusutrombopag (LUSU), an orally active, small-molecule thrombopoietin receptor agonist, was developed as an alternative to PT. lusutrombopag 0-13 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 55-78 34386595-3 2021 Lusutrombopag (LUSU), an orally active, small-molecule thrombopoietin receptor agonist, was developed as an alternative to PT. lusutrombopag 15-19 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 55-78 33466174-9 2021 Lusutrombopag, a thrombopoietin (TPO) receptor agonist, was orally administered for 7 days starting 7 days preoperatively to address the risks of bleeding. lusutrombopag 0-13 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 17-46 32238734-0 2021 New thrombopoietin receptor agonist (Lusutrombopag) is more effective in impaired renal function patients with chronic liver disease. lusutrombopag 37-50 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 4-27 32238734-1 2021 BACKGROUND: Thrombopoietin (TPO) receptor agonist, Lusutrombopag, is recently released to treat thrombocytopenia in chronic liver disease (CLD). lusutrombopag 51-64 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 12-41 34748184-3 2022 Lusutrombopag, a small-molecule thrombopoietin receptor agonist, is expected to be an alternative therapy to prophylactic PT. lusutrombopag 0-13 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 32-55 33644726-2 2021 Lusutrombopag is an oral, thrombopoietin receptor agonist approved for treatment of thrombocytopaenia associated with chronic liver disease in patients undergoing planned invasive procedures. lusutrombopag 0-13 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 26-49 32666123-0 2020 Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters. lusutrombopag 39-52 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 56-79 32666123-1 2020 PURPOSE: Drug-drug interaction (DDI) potentials of lusutrombopag, a thrombopoietin receptor agonist, on the activity of cytochrome P450 (CYP) 3A and of cyclosporine, which inhibits P-glycoprotein and breast cancer resistance protein, on lusutrombopag pharmacokinetics were assessed via clinical studies and physiologically based pharmacokinetic (PBPK) modeling. lusutrombopag 51-64 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 68-91 32205226-2 2020 Lusutrombopag is an agonist of the thrombopoietin receptor that activates platelet production. lusutrombopag 0-13 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 35-58 32813292-8 2020 As part of these guidelines, we outline the use of the US Food and Drug Administration-approved thrombopoietin receptor agonists avatrombopag and lusutrombopag as well tolerated and effective alternatives to platelet transfusion. lusutrombopag 146-159 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 96-119 32550846-1 2020 Lusutrombopag is a second oral thrombopoietin (TPO) receptor agonist that selectively acts on human TPO receptors. lusutrombopag 0-13 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 31-60 32841939-1 2021 BACKGROUND/AIMS: Lusutrombopag, a small-molecule thrombopoietin receptor agonist, is used to treat thrombocytopenia based on the results of a phase 3 trial, including data for single-use administration in patients with chronic liver disease (CLD) undergoing invasive procedures. lusutrombopag 17-30 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 49-72 32620282-4 2020 Recently, the thrombopoietin receptor agonists avatrombopag and lusutrombopag were studied and found efficacious for increasing platelet count in the outpatient setting for select patients with advanced liver disease who need a procedure. lusutrombopag 64-77 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 14-37 32510789-1 2020 BACKGROUND: The thrombopoietin receptor agonist Lusutrombopag was recently adapted for treatment of thrombocytopenia in chronic liver disease (CLD). lusutrombopag 48-61 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 16-39 29274361-0 2018 Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl. lusutrombopag 90-103 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 162-185 29274361-0 2018 Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl. lusutrombopag 90-103 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 186-191 29274361-1 2018 Lusutrombopag (S-888711), an oral small-molecule thrombopoietin receptor (TPOR) agonist, has gained first approval as a drug to treat thrombocytopenia of chronic liver disease in patients undergoing elective invasive procedures in Japan. lusutrombopag 0-13 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 49-72 29274361-1 2018 Lusutrombopag (S-888711), an oral small-molecule thrombopoietin receptor (TPOR) agonist, has gained first approval as a drug to treat thrombocytopenia of chronic liver disease in patients undergoing elective invasive procedures in Japan. lusutrombopag 0-13 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 74-78 29274361-1 2018 Lusutrombopag (S-888711), an oral small-molecule thrombopoietin receptor (TPOR) agonist, has gained first approval as a drug to treat thrombocytopenia of chronic liver disease in patients undergoing elective invasive procedures in Japan. lusutrombopag 15-23 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 49-72 29274361-1 2018 Lusutrombopag (S-888711), an oral small-molecule thrombopoietin receptor (TPOR) agonist, has gained first approval as a drug to treat thrombocytopenia of chronic liver disease in patients undergoing elective invasive procedures in Japan. lusutrombopag 15-23 MPL proto-oncogene, thrombopoietin receptor Homo sapiens 74-78